Observation on therapeutic effect of erigeron breviscapus injection combined with atorvastatin calcium in the treatment of acute ischemic stroke

doi:10.11958/20251797

Abstract

Abstract:

Objective To explore the clinical efficacy of erigeron breviscapus injection combined with atorvastatin calcium in patients with acute ischemic stroke (AIS) and its impact on systemic inflammatory markers. Methods A total of 151 AIS patients diagnosed and treated from January 2020 to December 2022 were selected and divided into the control group (n=75) and the study group (n=76) by random number method. The control group was given oral atorvastatin calcium treatment, and the study group was additionally treated with erigeron breviscapus injection on this basis. Before treatment, 7 d and 14 d after treatment, neurological function [National Institutes of Health Stroke Scale (NIHSS)], motor function[Fugl-Meyer Assessment (FMA)], activities of daily living [Barthel Index (ADL)] and systemic inflammatory markers such as tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), interleukin (IL)-6, lymphocytes (LYM), white blood cells (WBC), neutrophils (NEU) and platelets (PLT) were evaluated. Efficacy evaluation was conducted after 14 days of treatment. The adverse reactions of patients during the treatment period were recorded for safety assessment. Results The NIHSS score, TNF-α, CRP, IL-6, WBC, NEU and PLT levels were lower in the study group than those in the control group after 7 d and 14 d treatment, and decreased with the increase of treatment time (P<0.05). After 7 d and 14 d treatment, FMA score, ADL score and LYM level were higher in the study group than those in the control group, and increased with the prolongation of treatment time (P<0.05). TNF-α, CRP, IL-6, WBC, NEU and PLT were positively correlated with NIHSS score, and negatively correlated with FMA score and ADL score. LYM was negatively correlated with NIHSS score, and positively correlated with FMA score and ADL score (P<0.05). The total effective rate was higher in the study group than that of the control group (P<0.05). There was no significant difference in the incidence of total adverse reactions between the two groups (P>0.05). Conclusion After the combined treatment of AIS with erigeron breviscapus injection and atorvastatin calcium, the systemic inflammatory level of patients decreases significantly, the curative effect is good and the safety is high.

Key words: ischemic stroke, Deng Zhan Xi Xin Zhu She Ye, Atorvastatin, inflammation

CLC Number:

R743.3

Figures/Tables 8

References 20

[1]	LI J, QIU Y, ZHANG C, et al. The role of protein glycosylation in the occurrence and outcome of acute ischemic stroke[J]. Pharmacol Res, 2023,191:106726. doi:10.1016/j.phrs.2023.106726.
[2]	LIU W, MAN X, WANG Y, et al. Tirofiban mediates neuroprotective effects in acute ischemic stroke by reducing inflammatory response[J]. Neuroscience, 2024, 555:32-40. doi:10.1016/j.neuroscience.2024.07.016.
[3]	LI W, REN X, ZHANG L. Clinical efficacy of atorvastatin calcium combined with aspirin in patients with acute ischemic stroke and effect on neutrophils,lymphocytes and IL-33[J]. Exp Ther Med, 2020, 20(2):1277-1284. doi:10.3892/etm.2020.8820.
[4]	YANG L, TAO Y, LUO L, et al. Dengzhan Xixin injection derived from a traditional Chinese herb Erigeron breviscapus ameliorates cerebral ischemia/reperfusion injury in rats via modulation of mitophagy and mitochondrial apoptosis[J]. J Ethnopharmacol, 2022,288:114988. doi:10.1016/j.jep.2022.114988.
[5]	中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9):666-682.
	Neurology Branch of Chinese Medical Association, Cerebrovascular Disease Group of Neurology Branch of Chinese Medical Association. China Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2018[J]. Chinese Journal of Neurology, 2018, 51(9):666-682. doi:10.3760/cma.j.issn.1006-7876.2018.09.004.
[6]	YOU S, WANG Y, WANG X, et al. Twenty-four-hour post-thrombolysis NIHSS score as the strongest prognostic predictor after acute ischemic stroke:ENCHANTED study[J]. J Am Heart Assoc, 2024, 13(18):e036109. doi:10.1161/JAHA.124.036109.
[7]	WANG J, TIAN L, ZHANG Z, et al. Scalp-acupuncture for patients with hemiplegic paralysis of acute ischaemic stroke: a randomized controlled clinical trial[J]. J Tradit Chin Med, 2020, 40(5):845-854. doi:10.19852/j.cnki.jtcm.2020.05.015.
[8]	TANI T, IMAI S, FUSHIMI K. Rehabilitation of patients with acute ischemic stroke who required assistance before hospitalization contributes to improvement in activities of daily living:a nationwide database cohort study[J]. Arch Rehabil Res Clin Transl, 2022, 4(4):100224. doi:10.1016/j.arrct.2022.100224.
[9]	QIU Y M, ZHANG C L, CHEN A Q, et al. Immune cells in the BBB disruption after acute ischemic stroke:targets for immune therapy?[J]. Front Immunol, 2021,12:678744. doi:10.3389/fimmu.2021.678744.
[10]	DAMMAVALAM V, LIN S, NESSA S, et al. Neuroprotection during thrombectomy for acute ischemic stroke:a review of future therapies[J]. Int J Mol Sci, 2024, 25(2):891-906. doi:10.3390/ijms25020891.
[11]	THOMAS R G, KIM J H, KIM J H, et al. Treatment of ischemic stroke by atorvastatin-loaded PEGylated liposome[J]. Transl Stroke Res, 2024, 15(2):388-398. doi:10.1007/s12975-023-01125-9.
[12]	WANG Q, CHEN Z, GUO J, et al. Atorvastatin-induced tolerogenic dendritic cells improve cardiac remodeling by suppressing TLR-4/NF-κB activation after myocardial infarction[J]. Inflamm Res, 2023, 72(1):13-25. doi:10.1007/s00011-022-01654-3.
[13]	ZHANG J, HAN M, WANG S, et al. Study on the anti-mitochondrial apoptosis mechanism of Erigeron breviscapus injection based on UPLC-Q-TOF-MS metabolomics and molecular docking in rats with cerebral ischemia-reperfusion injury[J]. J Ethnopharmacol, 2024, 319(Pt 2):117310. doi:10.1016/j.jep.2023.117596.
[14]	AN H, TAO W, LIANG Y, et al. Dengzhanxixin injection ameliorates cognitive impairment through a neuroprotective mechanism based on mitochondrial preservation in patients with acute ischemic stroke[J]. Front Pharmacol, 2021,12:712436. doi:10.3389/fphar.2021.712436.
[15]	LIU G, LIANG Y, XU M, et al. Protective mechanism of Erigeron breviscapus injection on blood-brain barrier injury induced by cerebral ischemia in rats[J]. Sci Rep, 2021, 11(1):18451. doi:10.1038/s41598-021-97908-x.
[16]	LIU G, TANG G, LIANG W, et al. PK-PD correlation of erigeron breviscapus injection in the treatment of cerebral ischemia-reperfusion injury model rats[J]. J Mol Neurosci, 2021, 71(2):302-324. doi:10.1007/s12031-020-01651-3.
[17]	郎丰龙, 张强. rt-PA溶栓联合机械支架介入取栓对急性缺血性脑卒中患者炎性细胞因子和近期预后的影响[J]. 检验医学与临床, 2021, 18(1):104-107.
	LANG F L, ZHANG Q. Effect of thrombolysis with rt-PA combined with mechanical stent intervention on inflammatory cytokines and short-term prognosis in patients with acute ischemic stroke[J]. Laboratory Medicine and Clinical, 2021, 18(1):104-107. doi:10.3969/j.issn.1672-9455.2021.01.031.
[18]	李鑫, 张蔚, 王睿韬, 等. 依达拉奉右莰醇注射用浓溶液联合灯盏细辛注射液治疗急性缺血性脑卒中的临床效果[J]. 中国临床医生杂志, 2024, 52(3):299-302.
	LI X, ZHANG W, WANG R T, et al. Clinical effect of concentrated solution of edaravone and erigeron breviscapus injection on acute ischemic stroke[J]. China Journal of Clinicians, 2024, 52(3):299-302. doi:10.3969/j.issn.2095-8552.2024.03.012.
[19]	YU L, HUANG L, ZHAO Y, et al. Atorvastatin promotes pro/anti-inflammatory phenotypic transformation of microglia via Wnt/β-catenin pathway in hypoxic-ischemic neonatal rats[J]. Mol Neurobiol, 2024, 61(6):3559-3577. doi:10.1007/s12035-023-03777-y.
[20]	黄格朗, 谭治标, 廖香玲, 等. 灯盏细辛联合"中枢整合"技术对急性缺血性脑卒中患者下肢运动功能障碍的临床疗效[J]. 内科, 2023, 18(3):223-227.
	HUANG G L, TAN Z B, LIAO X L, et al. Clinical effect of erigeron breviscapus combined with "central integration" technique on motor dysfunction of lower limbs in patients with acute ischemic stroke[J]. Internal Medicine, 2023, 18(3):223-227. doi:10.16121/j.cnki.cn45-1347/r.2023.03.05.

组别	n	男性		年龄/岁		BMI/（kg/m²）		发病至入院时间/h
对照组	75	34（45.3）		62.36±8.12		22.42±2.48		4.25±1.36
研究组	76	37（48.7）		62.84±8.74		22.37±2.43		4.32±1.18
t或χ²		0.170		0.350		0.125		0.338
组别	合并基础病
组别	高血压		糖尿病		高血脂		冠心病		既往卒中史
对照组	33（44.0）		27（36.0）		22（29.3）		14（18.7）		8（10.7）
研究组	35（46.1）		24（31.6）		28（36.8）		17（22.4）		12（15.8）
χ²	0.064		0.330		0.961		0.317		0.862

组别	n	男性		年龄/岁		BMI/（kg/m²）		发病至入院时间/h
对照组	75	34（45.3）		62.36±8.12		22.42±2.48		4.25±1.36
研究组	76	37（48.7）		62.84±8.74		22.37±2.43		4.32±1.18
t或χ²		0.170		0.350		0.125		0.338
组别	合并基础病
组别	高血压		糖尿病		高血脂		冠心病		既往卒中史
对照组	33（44.0）		27（36.0）		22（29.3）		14（18.7）		8（10.7）
研究组	35（46.1）		24（31.6）		28（36.8）		17（22.4）		12（15.8）
χ²	0.064		0.330		0.961		0.317		0.862

组别	n	治疗前	治疗后7 d	治疗后14 d
对照组	75	21.54±5.27	18.21±4.85^a	15.48±3.69^ab
研究组	76	21.86±5.74	16.57±4.13^a	13.16±3.25^ab
t		0.368	2.238^＊	4.101^＊＊
F_组间/F_组内/F_交互		8.103^＊＊/11.170^＊＊/8.573^＊＊

组别	n	治疗前	治疗后7 d	治疗后14 d
对照组	75	21.54±5.27	18.21±4.85^a	15.48±3.69^ab
研究组	76	21.86±5.74	16.57±4.13^a	13.16±3.25^ab
t		0.368	2.238^＊	4.101^＊＊
F_组间/F_组内/F_交互		8.103^＊＊/11.170^＊＊/8.573^＊＊

组别	n	治疗前	治疗后7 d	治疗后14 d
对照组	75	34.76±8.31	41.64±10.47^a	48.52±13.87^ab
研究组	76	35.42±8.64	45.93±12.31^a	56.15±15.63^ab
t		0.478	2.305^＊	3.176^＊＊
F_组间/F_组内/F_交互		17.237^＊＊/11.003^＊＊/7.003^＊